| Year |
Citation |
Score |
| 2014 |
Chappell JC, Eisenhofer G, Owens MJ, Haber H, Lachno DR, Dean RA, Knadler MP, Nemeroff CB, Mitchell MI, Detke MJ, Iyengar S, Pangallo B, Lobo ED. Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects. Journal of Clinical Psychopharmacology. 34: 9-16. PMID 24346757 DOI: 10.1097/JCP.0000000000000061 |
0.318 |
|
| 2008 |
Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. International Clinical Psychopharmacology. 23: 161-9. PMID 18408530 DOI: 10.1097/YIC.0b013e3282f41d7e |
0.373 |
|
| 2005 |
Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Current Pharmaceutical Design. 11: 1475-93. PMID 15892657 DOI: 10.2174/1381612053764805 |
0.352 |
|
| 2002 |
Carlezon WA, Pliakas AM, Parow AM, Detke MJ, Cohen BM, Renshaw PF. Antidepressant-like effects of cytidine in the forced swim test in rats. Biological Psychiatry. 51: 882-9. PMID 12022961 DOI: 10.1016/S0006-3223(01)01344-0 |
0.408 |
|
| 2002 |
Chalon S, Bieck PR, Goldstein DJ, Detke MJ, Bymaster FP, Potter WZ, Demitrack MA. The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 26: 698-9; author reply . PMID 11927196 DOI: 10.1016/S0893-133X(01)00409-2 |
0.334 |
|
| 1999 |
Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology. 147: 162-7. PMID 10591883 DOI: 10.1007/S002130051156 |
0.576 |
|
| 1997 |
Detke MJ, Johnson J, Lucki I. Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Experimental and Clinical Psychopharmacology. 5: 107-12. PMID 9234045 DOI: 10.1037/1064-1297.5.2.107 |
0.648 |
|
| 1996 |
Detke MJ, Lucki I. Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Behavioural Brain Research. 73: 43-6. PMID 8788475 DOI: 10.1016/0166-4328(96)00067-8 |
0.678 |
|
| 1995 |
Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology. 121: 66-72. PMID 8539342 DOI: 10.1007/Bf02245592 |
0.704 |
|
| 1995 |
Detke MJ, Wieland S, Lucki I. Blockade of the antidepressant-like effects of 8-OH-DPAT, buspirone and desipramine in the rat forced swim test by 5HT1A receptor antagonists. Psychopharmacology. 119: 47-54. PMID 7675949 DOI: 10.1007/Bf02246053 |
0.591 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 1991 |
Detke MJ. Extinction of sequential conditioned inhibition Animal Learning & Behavior. 19: 345-354. DOI: 10.3758/Bf03197895 |
0.289 |
|
| 2007 |
Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. Journal of Clinical Psychopharmacology. 27: 672-6. PMID 18004135 DOI: 10.1097/jcp.0b013e31815a4412 |
0.284 |
|
| 2010 |
Mallinckrodt CH, Detke MJ, Prucka WR, Ruberg SJ, Molenberghs G. Considerations for Comparing a Test Drug with Standard of Care in Phase 2 Clinical Trials of Central Nervous System Disorders Drug Information Journal. 44: 443-452. DOI: 10.1177/009286151004400408 |
0.275 |
|
| 2007 |
Mallinckrodt CH, Meyers AL, Prakash A, Faries DE, Detke MJ. Simple options for improving signal detection in antidepressant clinical trials. Psychopharmacology Bulletin. 40: 101-14. PMID 17514189 |
0.264 |
|
| 2002 |
Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV. Duloxetine for the treatment of major depressive disorder. Psychopharmacology Bulletin. 36: 106-32. PMID 12858150 |
0.261 |
|
| 2007 |
Mallinckrodt CH, Prakash A, Houston JP, Swindle R, Detke MJ, Fava M. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology. 56: 73-85. PMID 18037817 DOI: 10.1159/000111537 |
0.256 |
|
| 2005 |
Thase ME, Tran PV, Wiltse C, Pangallo BA, Mallinckrodt C, Detke MJ. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. Journal of Clinical Psychopharmacology. 25: 132-40. PMID 15738744 DOI: 10.1097/01.jcp.0000155815.44338.95 |
0.25 |
|
| 2002 |
Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. Journal of Psychiatric Research. 36: 383-90. PMID 12393307 DOI: 10.1016/S0022-3956(02)00060-2 |
0.243 |
|
| 2007 |
Hudson JI, Perahia DG, Gilaberte I, Wang F, Watkin JG, Detke MJ. Duloxetine in the treatment of major depressive disorder: an open-label study. Bmc Psychiatry. 7: 43. PMID 17725843 DOI: 10.1186/1471-244X-7-43 |
0.242 |
|
| 2006 |
Perahia DG, Gilaberte I, Wang F, Wiltse CG, Huckins SA, Clemens JW, Montgomery SA, Montejo AL, Detke MJ. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. The British Journal of Psychiatry : the Journal of Mental Science. 188: 346-53. PMID 16582061 DOI: 10.1192/bjp.188.4.346 |
0.24 |
|
| 2003 |
Fishbain DA, Detke MJ. Analgesic effect of antidepressants [2] (multiple letters) Journal of Clinical Psychiatry. 64: 96-97. PMID 12590632 |
0.235 |
|
| 2003 |
Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ. Duloxetine in treatment of anxiety symptoms associated with depression. Depression and Anxiety. 18: 53-61. PMID 12964171 DOI: 10.1002/da.10122 |
0.226 |
|
| 2005 |
Dunner DL, D'Souza DN, Kajdasz DK, Detke MJ, Russell JM. Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression. Journal of Affective Disorders. 87: 115-9. PMID 15967235 DOI: 10.1016/j.jad.2005.02.017 |
0.221 |
|
| 2004 |
Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. Journal of Clinical Psychopharmacology. 24: 389-99. PMID 15232330 DOI: 10.1097/01.jcp.0000132448.65972.d9 |
0.221 |
|
| 2004 |
Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 14: 457-70. PMID 15589385 DOI: 10.1016/J.Euroneuro.2004.01.002 |
0.207 |
|
| 2005 |
Nelson JC, Wohlreich MM, Mallinckrodt CH, Detke MJ, Watkin JG, Kennedy JS. Duloxetine for the treatment of major depressive disorder in older patients. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 13: 227-35. PMID 15728754 DOI: 10.1176/appi.ajgp.13.3.227 |
0.198 |
|
| 2006 |
Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Psychiatry : the Journal of the Association of European Psychiatrists. 21: 367-78. PMID 16697153 DOI: 10.1016/j.eurpsy.2006.03.004 |
0.198 |
|
| 2002 |
Detke M, Lu Y, Goldstein D, Demitrack M. Duloxetine 60 mg QD is efficacious in the treatment of depression European Neuropsychopharmacology. 12: 215. DOI: 10.1016/S0924-977X(02)80233-4 |
0.197 |
|
| 2002 |
Detke M, Bitter I, Lu Y, Goldstein D, Demitrack M. Duloxetine 60 mg QD is efficacious in the treatment of depression European Psychiatry. 17: 98. DOI: 10.1016/S0924-9338(02)80445-X |
0.197 |
|
| 2006 |
Fava M, Detke MJ, Balestrieri M, Wang F, Raskin J, Perahia D. Management of depression relapse: re-initiation of duloxetine treatment or dose increase. Journal of Psychiatric Research. 40: 328-36. PMID 16678205 DOI: 10.1016/j.jpsychires.2005.06.005 |
0.196 |
|
| 2003 |
Mallinckrodt CH, Goldstein DJ, Detke MJ, Lu Y, Watkin JG, Tran PV. Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression. Primary Care Companion to the Journal of Clinical Psychiatry. 5: 19-28. PMID 15156243 |
0.192 |
|
| 2007 |
Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ. Use of effect size to determine optimal dose of duloxetine in major depressive disorder. Journal of Psychiatric Research. 41: 311-8. PMID 16934840 DOI: 10.1016/J.Jpsychires.2006.06.013 |
0.187 |
|
| 2009 |
Perahia DG, Maina G, Thase ME, Spann ME, Wang F, Walker DJ, Detke MJ. Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. The Journal of Clinical Psychiatry. 70: 706-16. PMID 19552867 DOI: 10.4088/JCP.08m04756 |
0.186 |
|
| 2007 |
Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, Ball SG, Russell JM. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Primary Care Companion to the Journal of Clinical Psychiatry. 9: 100-7. PMID 17607331 |
0.185 |
|
| 2002 |
Goldstein D, Bitter I, Lu Y, Detke M, Wiltse C, Mallinckrodt C, Demitrack M. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine European Psychiatry. 17: 98. DOI: 10.1016/S0924-9338(02)80446-1 |
0.185 |
|
| 2003 |
Khan A, Detke M, Khan SRF, Mallinckrodt C. Placebo response and antidepressant clinical trial outcome Journal of Nervous and Mental Disease. 191: 211-218. PMID 12695731 DOI: 10.1097/00005053-200304000-00001 |
0.183 |
|
| 2002 |
Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. The Journal of Clinical Psychiatry. 63: 308-15. PMID 12000204 |
0.181 |
|
| 2007 |
Shelton RC, Prakash A, Mallinckrodt CH, Wohlreich MM, Raskin J, Robinson MJ, Detke MJ. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. International Journal of Clinical Practice. 61: 1337-48. PMID 17627710 DOI: 10.1111/j.1742-1241.2007.01444.x |
0.181 |
|
| 2014 |
Shen JH, Zhao Y, Rosenzweig-Lipson S, Popp D, Williams JB, Giller E, Detke MJ, Kane JM. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. Journal of Psychiatric Research. 53: 14-22. PMID 24613032 DOI: 10.1016/j.jpsychires.2014.02.012 |
0.181 |
|
| 2008 |
Fishbain DA, Detke MJ, Wernicke J, Chappell AS, Kajdasz DK. The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder. Current Medical Research and Opinion. 24: 3105-15. PMID 18828958 DOI: 10.1185/03007990802429627 |
0.179 |
|
| 2008 |
Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depression and Anxiety. 25: 182-9. PMID 17311303 DOI: 10.1002/da.20271 |
0.179 |
|
| 2008 |
Kornstein SG, Dunner DL, Meyers AL, Whitmyer VG, Mallinckrodt CH, Wohlreich MM, Detke MJ, Hollandbeck MS, Greist JH. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. The Journal of Clinical Psychiatry. 69: 1383-92. PMID 19193339 |
0.178 |
|
| 2006 |
Nelson JC, Lu Pritchett Y, Martynov O, Yu JY, Mallinckrodt CH, Detke MJ. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Primary Care Companion to the Journal of Clinical Psychiatry. 8: 212-9. PMID 16964316 |
0.177 |
|
| 2014 |
Fava M, Freeman M, Williams J, Detke M. EPA-1780 – Are different methods to reduce placebo response in cns trials mutually exclusive or have additive effects? European Psychiatry. 29: 1. DOI: 10.1016/S0924-9338(14)78903-5 |
0.176 |
|
| 2007 |
Shelton RC, Andorn AC, Mallinckrodt CH, Wohlreich MM, Raskin J, Watkin JG, Detke MJ. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. International Clinical Psychopharmacology. 22: 348-55. PMID 17917553 DOI: 10.1097/YIC.0b013e32821c6189 |
0.175 |
|
| 2008 |
Allgulander C, Nutt D, Detke M, Erickson J, Spann M, Walker D, Ball SG, Russell JM. A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder Journal of Psychopharmacology. 22: 417-425. PMID 18635722 DOI: 10.1177/0269881108091588 |
0.175 |
|
| 2005 |
Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, Watkin JG, Detke MJ. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. The Journal of Clinical Psychiatry. 66: 686-92. PMID 15960560 |
0.171 |
|
| 2007 |
Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J. Duloxetine as an SNRI treatment for generalized anxiety disorder: Results from a placebo and active-controlled trial International Clinical Psychopharmacology. 22: 167-174. PMID 17414743 DOI: 10.1097/Yic.0B013E32807Fb1B2 |
0.171 |
|
| 2005 |
Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ. Time course of depression-symptom improvement during treatment with duloxetine. Depression and Anxiety. 21: 170-7. PMID 16035056 DOI: 10.1002/da.20071 |
0.17 |
|
| 2010 |
Mallinckrodt CH, Detke MJ, Prucka WR, Ruberg SJ, Molenberghs G. Considerations for comparing a test drug with standard of care in phase 2 clinical trials of central nervous system disorders Drug Information Journal. 44: 443-452. |
0.169 |
|
| 2004 |
Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics. 45: 17-28. PMID 14709757 DOI: 10.1176/appi.psy.45.1.17 |
0.168 |
|
| 2008 |
Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 136: 432-44. PMID 18395345 DOI: 10.1016/j.pain.2008.02.024 |
0.165 |
|
| 2005 |
Brannan SK, Mallinckrodt CH, Detke MJ, Watkin JG, Tollefson GD. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies. Journal of Psychiatric Research. 39: 161-72. PMID 15589564 DOI: 10.1016/j.jpsychires.2004.05.005 |
0.161 |
|
| 2008 |
Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, Russell JM. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 18: 673-81. PMID 18559291 DOI: 10.1016/j.euroneuro.2008.05.002 |
0.156 |
|
| 2010 |
Mallinckrodt CH, Detke MJ, Prucka WR, Ruberg SJ, Molenberghs G. Design Archetypes for Phase 2 Clinical Trials in Central Nervous System Disorders Drug Information Journal. 44: 421-430. DOI: 10.1177/009286151004400406 |
0.153 |
|
| 2004 |
Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism. 50: 2974-84. PMID 15457467 DOI: 10.1002/art.20485 |
0.153 |
|
| 2006 |
Pritchett Y, McCarberg B, Watkin J, Chappell A, Robinson M, Xu J, Rotz B, Wernicke J, Detke M, Iyengar S, Henck J, Bymaster F, Callaghan J, Knadler M, Thase M, et al. Abstracts from the ASENT 2006 Annual Meeting March 8–11, 2006 Neurorx. 3: 407-415. DOI: 10.1016/J.Nurx.2006.05.010 |
0.153 |
|
| 2010 |
Pangallo BA, Zhang Q, Desaiah D, Perahia DG, Detke MJ, Kennedy SH. Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials. Current Medical Research and Opinion. 26: 2643-51. PMID 20932222 DOI: 10.1185/03007995.2010.522157 |
0.151 |
|
| 2003 |
Wohlreich M, Mallinckrodt C, Lu Y, Detke M. The efficacy of duloxetine (60 mg qd) in the treatment of painful physical symptoms in patients with major depressive disorder Journal of Psychosomatic Research. 55: 157. DOI: 10.1016/S0022-3999(03)00200-9 |
0.151 |
|
| 2004 |
Mallinckrodt CH, Raskin J, Wohlreich MM, Watkin JG, Detke MJ. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. Bmc Psychiatry. 4: 26. PMID 15355546 DOI: 10.1186/1471-244X-4-26 |
0.15 |
|
| 2004 |
Viktrup L, Pangallo BA, Detke MJ, Zinner NR. Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary Incontinence. Primary Care Companion to the Journal of Clinical Psychiatry. 6: 65-73. PMID 15254599 |
0.148 |
|
| 2013 |
Popp D, Burch R, Williams J, Price L, Detke M. 2210 – A phase II randomized, double-blind, placebo-controlled trial of GLYX-13 for the rapid treatment of major depressive disorder using central ratings European Psychiatry. 28: 1. DOI: 10.1016/S0924-9338(13)77083-4 |
0.147 |
|
| 2005 |
Burt VK, Wohlreich MM, Mallinckrodt CH, Detke MJ, Watkin JG, Stewart DE. Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years. Psychosomatics. 46: 345-54. PMID 16000678 DOI: 10.1176/appi.psy.46.4.345 |
0.145 |
|
| 2003 |
Detke M, Gilaberte I, Perahia D, Wang F, McNamara R, Tran P, Miner C, Montgomery S. P.1.204 Duloxetine vs placebo in the prevention of relapse of major depressive disorder European Neuropsychopharmacology. 13: S261-S262. DOI: 10.1016/S0924-977X(03)91914-6 |
0.145 |
|
| 2005 |
Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 116: 109-18. PMID 15927394 DOI: 10.1016/j.pain.2005.03.029 |
0.143 |
|
| 2006 |
Alpert J, Detke M, Lecrubier Y, Schläpfer T. C.12.01 Current controversies in depression treatment: a hot topics panel European Neuropsychopharmacology. 16: S581. DOI: 10.1016/S0924-977X(06)70842-2 |
0.142 |
|
| 2013 |
Popp D, Burch R, Williams J, Price L, Detke M. P.2.b.027 A phase II randomized, double-blind, placebo-controlled trial of GLYX-13 for the rapid treatment of major depressive disorder (MDD) using central ratings European Neuropsychopharmacology. 23: S334-S335. DOI: 10.1016/S0924-977X(13)70526-1 |
0.142 |
|
| 2010 |
Mease PJ, Russell IJ, Kajdasz DK, Wiltse CG, Detke MJ, Wohlreich MM, Walker DJ, Chappell AS. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Seminars in Arthritis and Rheumatism. 39: 454-64. PMID 19152958 DOI: 10.1016/j.semarthrit.2008.11.001 |
0.142 |
|
| 2002 |
Lu Y, Tran P, Detke M. Remission rates during treatment with duloxetine in patients with major depressive disorder European Neuropsychopharmacology. 12: 214. DOI: 10.1016/S0924-977X(02)80230-9 |
0.137 |
|
| 2010 |
Mallinckrodt CH, Detke MJ, Prucka WR, Ruberg SJ, Molenberghs G. Considerations for Using Positive Controls in Phase 2 Clinical Trials of Central Nervous System Disorders Drug Information Journal. 44: 431-441. DOI: 10.1177/009286151004400407 |
0.136 |
|
| 2008 |
Pollack MH, Endicott J, Liebowitz M, Russell J, Detke M, Spann M, Ball S, Swindle R. Examining quality of life in patients with generalized anxiety disorder: Clinical relevance and response to duloxetine treatment Journal of Psychiatric Research. 42: 1042-1049. PMID 18221755 DOI: 10.1016/J.Jpsychires.2007.11.006 |
0.136 |
|
| 2007 |
Endicott J, Russell JM, Raskin J, Detke MJ, Erickson J, Ball SG, Marciniak M, Swindle RW. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. The Journal of Clinical Psychiatry. 68: 518-24. PMID 17474806 DOI: 10.4088/Jcp.V68N0405 |
0.135 |
|
| 2011 |
Montejo AL, Perahia DG, Spann ME, Wang F, Walker DJ, Yang CR, Detke MJ. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder. The Journal of Sexual Medicine. 8: 773-82. PMID 21091877 DOI: 10.1111/j.1743-6109.2010.02113.x |
0.134 |
|
| 2014 |
Potter WZ, Mallinckrodt CH, Detke MJ. Controlling placebo response in drug development: Lessons learned from psychopharmacology Pharmaceutical Medicine. 28: 53-65. DOI: 10.1007/s40290-014-0052-8 |
0.132 |
|
| 2007 |
Mallinckrodt C, Chuang-Stein C, McSorley P, Schwartz J, Archibald DG, Perahia DG, Detke MJ, Alphs L. A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressant. Pharmaceutical Statistics. 6: 9-22. PMID 17238129 DOI: 10.1002/pst.234 |
0.13 |
|
| 2002 |
Goldstein D, Detke M, Lu Y, Demitrack M. The antidepressant duloxetine reduces anxiety symptom severity European Neuropsychopharmacology. 12: 213. DOI: 10.1016/S0924-977X(02)80229-2 |
0.13 |
|
| 2015 |
Williams JB, Kobak KA, Giller E, Reasner DS, Curry L, Detke MJ. Comparison of Site-Based Versus Central Ratings in a Study of Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology. PMID 26488677 DOI: 10.1097/JCP.0000000000000422 |
0.128 |
|
| 2004 |
Swindle R, Mallinckrodt C, Rosebaum J, Lu Y, Watkin J, Ghandi P, Detke M. P.1.040 Efficacy of duloxetine treatment: Analysis of pooled data from six placebo- and SSRI-controlled clinical trials European Neuropsychopharmacology. 14: S190. DOI: 10.1016/S0924-977X(04)80129-9 |
0.127 |
|
| 2009 |
Schneider E, Skljarevski V, Desaiah D, Zhang Q, Chappell A, Detke M, Gross J. Wirkung von einmal täglich 60mg Duloxetin bei Patienten mit Schmerzen bei diabetischer Polyneuropathie: Ergebnisse einer offenen Langzeitstudie Diabetologie Und Stoffwechsel. 4. DOI: 10.1055/S-0029-1221964 |
0.125 |
|
| 2004 |
Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? The Journal of Clinical Psychiatry. 65: 521-30. PMID 15119915 DOI: 10.4088/JCP.v65n0411 |
0.125 |
|
| 2011 |
Detke M, Williams J, Kobak K, Ellis A, Giller E, Brown B, Reines S, Kane J, Popp D. P.8.a.013 The challenge of subject selection in clinical trials European Neuropsychopharmacology. 21: S618. DOI: 10.1016/S0924-977X(11)71011-2 |
0.124 |
|
| 2003 |
Wohlreich M, Brannan S, Mallinckrodt C, Detke M, Lu Y, Watkin J, Tollefson G. P.1.035 Onset of improvement in emotional and painful physical symptoms of depression with duloxetine treatment European Neuropsychopharmacology. 13: S189. DOI: 10.1016/S0924-977X(03)91746-9 |
0.114 |
|
| 2002 |
Tran P, Mallinckrodt C, Detke M, Goldstein D, Demitrack M. Safety and tolerability of the antidepressant duloxetine European Neuropsychopharmacology. 12: 215-216. DOI: 10.1016/S0924-977X(02)80235-8 |
0.11 |
|
| 2009 |
Skljarevski V, Desaiah D, Zhang Q, Chappell AS, Detke MJ, Gross JL, Ziegler D. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain. Diabetes/Metabolism Research and Reviews. 25: 623-31. PMID 19637208 DOI: 10.1002/dmrr.1000 |
0.107 |
|
| 2003 |
Goldstein D, Lu Y, Iyengar S, Detke M. Duloxetine reduces painful physical symptoms associated with depression Journal of Psychosomatic Research. 55: 164. DOI: 10.1016/S0022-3999(03)00234-4 |
0.105 |
|
| 2006 |
Mallinckrodt CH, Detke MJ, Kaiser CJ, Watkin JG, Molenberghs G, Carroll RJ. Comparing onset of antidepressant action using a repeated measures approach and a traditional assessment schedule. Statistics in Medicine. 25: 2384-97. PMID 16217850 DOI: 10.1002/Sim.2309 |
0.103 |
|
| 2010 |
Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, Iyengar S, Atkinson JH, Backonja M. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine. 35: E578-85. PMID 20461028 DOI: 10.1097/BRS.0b013e3181d3cef6 |
0.103 |
|
| 2013 |
Chappell JC, Kovacs R, Haber H, Wright R, Mitchell MI, Detke M, Pangallo B. Evaluation of the effects of duloxetine and escitalopram on 24-hour heart rate variability: A mechanistic study using heart rate variability as a pharmacodynamic measure Journal of Clinical Psychopharmacology. 33: 236-239. PMID 23422380 DOI: 10.1097/JCP.0b013e31828567b6 |
0.102 |
|
| 2008 |
Chappell AS, Bradley LA, Wiltse C, Detke MJ, D'Souza DN, Spaeth M. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine. 1: 91-102. PMID 20428412 |
0.099 |
|
| 2003 |
Thase M, Lu Y, Joliat M, Detke M. P.1.096 Remission rates in double-blind, placebo-controlled clinical trials of duloxetine with SSRI as a comparator European Neuropsychopharmacology. 13: S215. DOI: 10.1016/S0924-977X(03)91806-2 |
0.098 |
|
| 2003 |
Wohlreich M, Fava M, Mallinckrodt C, Watkin J, Detke M. Does the alleviation of painful physical symptoms associated with depression lead to higher remission rates? Journal of Psychosomatic Research. 55: 157-158. DOI: 10.1016/S0022-3999(03)00201-0 |
0.096 |
|
| 2015 |
Kiluk BD, Carroll KM, Duhig A, Falk DE, Kampman K, Lai S, Litten RZ, McCann DJ, Montoya ID, Preston KL, Skolnick P, Weisner C, Woody G, Chandler R, Detke MJ, et al. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug and Alcohol Dependence. PMID 26652899 DOI: 10.1016/J.Drugalcdep.2015.11.004 |
0.094 |
|
| 2012 |
Williams J, Popp D, Kobak K, Detke M. P-641 - The importance of rigor in post-baseline assessments in cns clinical trials European Psychiatry. 27: 1. DOI: 10.1016/S0924-9338(12)74808-3 |
0.093 |
|
| 2011 |
Williams J, Kobak K, Detke M. P.8.a.014 The importance of rigor in post-baseline assessments in CNS clinical trials European Neuropsychopharmacology. 21: S618-S619. DOI: 10.1016/S0924-977X(11)71012-4 |
0.093 |
|
| 2006 |
DETKE M, IYENGAR S, HENCK J, BYMASTER F, CALLAGHAN J, KNADLER M, CHAPPELL A, WERNICKE J, THASE M. Cardiovascular Effects of Duloxetine: Preclinical and Clinical Findings Neurorx. 3: 407-408. DOI: 10.1016/J.NURX.2006.05.012 |
0.09 |
|
| 2016 |
Detke M, Negash S, Webber-Lind B, Sorantin P, Williams J. Error reductions over time in Virgil eCOA versus paper-based administrations in psychiatry trials European Neuropsychopharmacology. 26: S470-S471. DOI: 10.1016/S0924-977X(16)31470-5 |
0.089 |
|
| 2012 |
Popp D, Williams J, Kobak K, Boehm P, Detke M. P3-382: The role of expectation bias in neurocognitive clinical trials Alzheimer's & Dementia. 8: P589-P590. DOI: 10.1016/j.jalz.2012.05.1607 |
0.083 |
|
| 2009 |
Skljarevski V, Ossanna M, Liu-Seifert H, Zhang Q, Chappell A, Iyengar S, Detke M, Backonja M. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain European Journal of Neurology. 16: 1041-1048. PMID 19469829 DOI: 10.1111/j.1468-1331.2009.02648.x |
0.081 |
|
| 2012 |
Williams J, Popp D, Osman D, Cohen E, Detke M. P.3.a.010 The use of the 16 item Negative Symptom Assessment (NSA-16) by videoconferencing in a clinical trial European Neuropsychopharmacology. 22: S309. DOI: 10.1016/S0924-977X(12)70472-8 |
0.08 |
|
| 1989 |
Detke MJ, Brandon SE, Weingarten HP, Rodin J, Wagner AR. Modulation of behavioral and insulin responses by contextual stimuli paired with food. Physiology & Behavior. 45: 845-51. PMID 2675142 DOI: 10.1016/0031-9384(89)90305-3 |
0.079 |
|
| 2012 |
Williams J, Popp D, Reines S, Detke M. P.1.i.009 Some urban legends of CNS clinical trial methodology: unsuccessful solutions to the problem of failed trials European Neuropsychopharmacology. 22: S223-S224. DOI: 10.1016/S0924-977X(12)70329-2 |
0.077 |
|
| 2012 |
Williams J, Popp D, Osman D, Cohen E, Detke M. Poster #177 THE USE OF THE NSA-16 BY VIDEOCONFERENCING IN A CLINICAL TRIAL Schizophrenia Research. 136: S344-S345. DOI: 10.1016/S0920-9964(12)71009-5 |
0.075 |
|
| 2013 |
Williams J, Popp D, Osman D, Cohen E, Detke M. 1922 – The evaluation of negative symptoms by videoconferencing in a clinical trial European Psychiatry. 28: 1. DOI: 10.1016/S0924-9338(13)76868-8 |
0.074 |
|
| 2007 |
Bodkin JA, Pope HG, Detke MJ, Hudson JI. Is PTSD caused by traumatic stress? Journal of Anxiety Disorders. 21: 176-82. PMID 17055216 DOI: 10.1016/j.janxdis.2006.09.004 |
0.074 |
|
| 2010 |
Detke M, Williams J, Kobath K, Ellis A, Giller E, Leon A, Reines S, Kane J. THE CHALLENGE OF PATIENT ASCERTAINMENT IN CLINICAL TRIALS – NEW DATA Schizophrenia Research. 117: 406. DOI: 10.1016/j.schres.2010.02.741 |
0.073 |
|
| 2012 |
Popp D, Williams JB, Sorantin P, Detke M. P2-304: Guidelines for reporting clinical trial methodology research: The seven deadly sins Alzheimer's & Dementia. 8: P369-P370. DOI: 10.1016/j.jalz.2012.05.1013 |
0.067 |
|
| 2009 |
Shoemaker S, Backonja MM, Chappell A, Detke M, Murray I, Skljarevski V, Zhang S. Poster 55: Maintenance of Effect of Duloxetine in Patients With Chronic Lower Back Pain Pm&R. 1: S127-S128. DOI: 10.1016/j.pmrj.2009.08.072 |
0.067 |
|
| 2009 |
Skljarevski V, Zhang S, Chappell A, Detke M, Murray I, Backonja M. 674 MAINTENANCE OF EFFECT OF DULOXETINE IN PATIENTS WITH CHRONIC LOW BACK PAIN European Journal of Pain. 13. DOI: 10.1016/S1090-3801(09)60677-7 |
0.064 |
|
| 2004 |
Mallinckrodt CH, Kaiser CJ, Watkin JG, Detke MJ, Molenbergs G, Carroll RJ. Type 1 error rates from likelihood-based repeated measures analyses of incomplete longitudinal data Pharmaceutical Statistics. 3: 171-186. DOI: 10.1002/Pst.131 |
0.063 |
|
| 2013 |
Williams J, Davis D, Popp D, Gross J, Salvucci D, Detke M. 1902 – Feasibility of centralized ratings for mental health safety screening in a non-psychiatric clinical trial European Psychiatry. 28: 1. DOI: 10.1016/S0924-9338(13)76853-6 |
0.06 |
|
| 2010 |
Mallinckrodt CH, Detke MJ, Prucka WR, Ruberg SJ, Molenberghs G. Design archetypes for phase 2 clinical trials in central nervous system disorders Drug Information Journal. 44: 421-430. |
0.056 |
|
| 2010 |
Mallinckrodt CH, Detke MJ, Prucka WR, Ruberg SJ, Molenberghs G. Considerations for using positive controls in phase 2 clinical trials of central nervous system disorders Drug Information Journal. 44: 431-441. |
0.053 |
|
| 2015 |
Detke M, Echevarria B, Osman D, Garzio L, Williams J. P.1.k.033 A new platform to improve quality of PANNS and MADRS administration European Neuropsychopharmacology. 25: S371-S372. DOI: 10.1016/S0924-977X(15)30479-X |
0.053 |
|
| 2017 |
Detke M, Connor G, Kelsh D, Straub J, Robbins A, Gloff C, Goeders N. A phase 1b study of potential safety and pharmacokinetic interactions between cocaine and EMB-001, with exploratory efficacy measures European Neuropsychopharmacology. 27: S1073. DOI: 10.1016/S0924-977X(17)31868-0 |
0.052 |
|
| 2013 |
Williams J, Popp D, Price L, Gross J, Davis D, Salvucci D, Detke M. P.8.b.004 Feasibility of centralised ratings for mental health safety screening in a dermatology trial European Neuropsychopharmacology. 23: S621-S622. DOI: 10.1016/S0924-977X(13)70987-8 |
0.051 |
|
| 2010 |
Detke M. IMPROVING SIGNAL DETECTION IN SCHIZOPHRENIA CLINICAL TRIALS Schizophrenia Research. 117: 138. DOI: 10.1016/j.schres.2010.02.107 |
0.041 |
|
| 2009 |
Wilhelm S, Skljarevski V, Desaiah D, Zhang Q, Chappell A, Detke M, Schneider E, Gross J. Aufrechterhaltung der Wirkung von Duloxetin bei Patienten mit Schmerzen bei diabetischer Polyneuropathie Aktuelle Neurologie. 36. DOI: 10.1055/s-0029-1238539 |
0.039 |
|
| 2012 |
Williams J, Popp D, Kobak K, Detke M. P-640 - The power of expectation bias European Psychiatry. 27: 1. DOI: 10.1016/S0924-9338(12)74807-1 |
0.022 |
|
| 2011 |
Williams J, Popp D, Kobak K, Detke M. P.8.a.015 The power of expectation bias European Neuropsychopharmacology. 21: S619. DOI: 10.1016/S0924-977X(11)71013-6 |
0.022 |
|
| 2012 |
Popp D, Williams J, Cohen E, Detke M. Poster #176 NSA-16 REVISITED: IDENTIFYING LATENT FACTORS OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Schizophrenia Research. 136: S344. DOI: 10.1016/S0920-9964(12)71008-3 |
0.017 |
|
| 2009 |
Aboud E, Bonnard C, Chappell A, Skljareversuski V, Desaiah D, Zhang Q, Detke M, Gross J, Pechtner V. O80 Évaluation de l’effet de la duloxétine dans la neuropathie diabétique périphérique douloureuse Diabetes & Metabolism. 35: A21. DOI: 10.1016/S1262-3636(09)71772-0 |
0.01 |
|
| 2007 |
Iyengar S, Pritchett Y, Hall J, Chappell A, Wernicke J, Goldstein D, Simmons R, Detke M, Shen S, D'Souza D, Schneider E, Robinson M. Die Zeit bis zum Ansprechen auf Duloxetin: Ergebnisse zur Übersicht über die Daten aus Zeitdauer bis zum Ansprechen aus präklinischen und klinischen Studien zu neuropathischen Schmerzen Diabetologie Und Stoffwechsel. 2. DOI: 10.1055/S-2007-982355 |
0.01 |
|
| 2006 |
Pritchett Y, McCarberg B, Watkin J, Chappell A, Robinson M, Xu J, Rotz B, Wernicke J, Detke M, Iyengar S, Henck J, Bymaster F, Callaghan J, Knadler M, Thase M, et al. Abstracts from the ASENT 2006 Annual Meeting March 8–11, 2006 Neurotherapeutics. 3: 407-415. DOI: 10.1007/bf03206663 |
0.01 |
|
| Hide low-probability matches. |